GeoVax Labs, Inc. is aiming for the underserved niche of immunocompromised people who are unable to benefit from the current crop of US Food and Drug Administration-authorized COVID-19 vaccines with a vaccine able to induce antibody as well as T-cell responses to parts of the SARS-CoV-2 virus, and thus protect against new and emerging variants like Omicron. And the firm now has early Phase II data for the vaccine, GEO-CM04S1, indicating antibody and T-cell responses in patients with blood cancers.
Early Data For GeoVax COVID-19 Vaccine Point To Efficacy In Immunocompromised Population
The company unveiled antibody and T-cell responses in patients with blood cancers and also plans to explore GM-CM04S1 in additional immunocompromised populations, such as lupus patients.
